Daraxonrasib, a new pancreatic cancer drug targeting RAS mutations found in over 90% of cases, showe...
New pancreatic cancer pill nearly doubles survival time in breakthrough trial
Daraxonrasib, a new pancreatic cancer drug targeting RAS mutations found in over 90% of cases, showed promising results in the first human trial led by the...
Author: Fox News
Read Original Article